CL2020003457A1 - Oligonucleótidos para modular la expresión de tau - Google Patents
Oligonucleótidos para modular la expresión de tauInfo
- Publication number
- CL2020003457A1 CL2020003457A1 CL2020003457A CL2020003457A CL2020003457A1 CL 2020003457 A1 CL2020003457 A1 CL 2020003457A1 CL 2020003457 A CL2020003457 A CL 2020003457A CL 2020003457 A CL2020003457 A CL 2020003457A CL 2020003457 A1 CL2020003457 A1 CL 2020003457A1
- Authority
- CL
- Chile
- Prior art keywords
- oligonucleotides
- tau
- modulate
- expression
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26004—Ribonuclease H (3.1.26.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Abstract
La presente invención se refiere a oligonucleótidos antisentido que pueden modular la expresión de Tau en una célula diana. Los oligonucleótidos se hibridan a mARN de MAPT. La presente invención, además, se refiere a conjugados del oligonucleótido y composiciones farmacéuticas y métodos para el tratamiento de taupatías, enfermedad de Alzheimer, demencia frontotemporal (FTD), FTDP-17, parálisis supranuclear progresiva (PSP), encefalopatía traumática crónica (CTE), degeneración ganglionar corticobasal (CBD), epilepsia, síndrome de Dravet, depresión, trastornos convulsivos y trastornos motores.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2021001071A CL2021001071A1 (es) | 2018-07-03 | 2021-04-26 | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) |
CL2021001072A CL2021001072A1 (es) | 2018-07-03 | 2021-04-26 | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862693851P | 2018-07-03 | 2018-07-03 | |
US201862726005P | 2018-08-31 | 2018-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020003457A1 true CL2020003457A1 (es) | 2021-06-04 |
Family
ID=67439176
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020003457A CL2020003457A1 (es) | 2018-07-03 | 2020-12-31 | Oligonucleótidos para modular la expresión de tau |
CL2021001071A CL2021001071A1 (es) | 2018-07-03 | 2021-04-26 | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) |
CL2021001072A CL2021001072A1 (es) | 2018-07-03 | 2021-04-26 | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001071A CL2021001071A1 (es) | 2018-07-03 | 2021-04-26 | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) |
CL2021001072A CL2021001072A1 (es) | 2018-07-03 | 2021-04-26 | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) |
Country Status (18)
Country | Link |
---|---|
US (4) | US11279929B2 (es) |
EP (1) | EP3818159A1 (es) |
JP (2) | JP7102557B2 (es) |
KR (2) | KR20230143199A (es) |
CN (1) | CN112567033A (es) |
AU (2) | AU2019297391B2 (es) |
BR (1) | BR112020026973A2 (es) |
CA (1) | CA3103054A1 (es) |
CL (3) | CL2020003457A1 (es) |
CR (3) | CR20210178A (es) |
IL (1) | IL279056A (es) |
MX (1) | MX2020013366A (es) |
PE (2) | PE20210346A1 (es) |
PH (1) | PH12020552276A1 (es) |
RU (1) | RU2768285C1 (es) |
SG (1) | SG11202012759XA (es) |
TW (1) | TW202020151A (es) |
WO (1) | WO2020007892A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2866392C (en) | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
CN203618139U (zh) * | 2012-08-21 | 2014-05-28 | 特电株式会社 | 流体加热装置 |
CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
CA3103054A1 (en) | 2018-07-03 | 2020-01-09 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating tau expression |
CN115210377A (zh) * | 2020-03-01 | 2022-10-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
IL310332A (en) * | 2021-07-23 | 2024-03-01 | Biogen Ma Inc | Methods for reducing TAU expression |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
EP0724447B1 (en) | 1991-10-24 | 2003-05-07 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
NZ513402A (en) | 1999-02-12 | 2003-06-30 | Sankyo Co | Novel nucleosides and oligonucleotide analogues |
CN102180924A (zh) | 1999-05-04 | 2011-09-14 | 桑塔里斯制药公司 | L-核糖-lna类似物 |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
ES2607471T3 (es) | 2002-11-18 | 2017-03-31 | Roche Innovation Center Copenhagen A/S | Diseño antisentido |
US7250289B2 (en) * | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US8350021B2 (en) | 2003-06-12 | 2013-01-08 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US7374927B2 (en) | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
US20060263798A1 (en) | 2005-02-11 | 2006-11-23 | International Business Machines Corporation | System and method for identification of MicroRNA precursor sequences and corresponding mature MicroRNA sequences from genomic sequences |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
ES2516815T3 (es) | 2006-01-27 | 2014-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6 |
WO2007106407A2 (en) | 2006-03-10 | 2007-09-20 | Wyeth | Microarray for monitoring gene expression in multiple strains of streptococcus pneumoniae |
CA2651042A1 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
EP2285819B1 (en) | 2008-04-04 | 2013-10-16 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
US20110118337A1 (en) | 2008-07-10 | 2011-05-19 | Merck Sharp & Dohme Corp. | Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
WO2010080129A2 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
RU2597972C2 (ru) | 2010-10-22 | 2016-09-20 | Курна Инк. | Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua |
CN103370415B (zh) | 2010-10-28 | 2017-05-31 | 本尼特生物制药有限公司 | Hbv治疗 |
US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
WO2012143379A1 (en) | 2011-04-20 | 2012-10-26 | Roche Glycart Ag | Method and constructs for the ph dependent passage of the blood-brain-barrier |
EP3505528B1 (en) | 2011-04-21 | 2020-11-25 | Ionis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
US8809293B2 (en) | 2011-06-30 | 2014-08-19 | Arrowhead Madison Inc. | Compositions and methods for inhibiting gene expression of hepatitis B virus |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
US9518101B2 (en) | 2011-09-19 | 2016-12-13 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
CA2866392C (en) | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
WO2013166264A2 (en) | 2012-05-02 | 2013-11-07 | University Of Georgia Research Foundation, Inc. | Methods for altering virus replication |
EA201492119A1 (ru) * | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии apoa1 и abca1 |
CA2878945A1 (en) | 2012-07-13 | 2014-01-16 | Wave Life Sciences Pte. Ltd. | Chiral control |
EP2890789A1 (en) | 2012-08-31 | 2015-07-08 | Aptamir Therapeutics, Inc. | Mirna modulators of chronic visceral inflammation |
MX363068B (es) | 2012-11-15 | 2019-03-07 | Roche Innovation Ct Copenhagen As | Conjugados de oligonucleotido. |
JP6629716B2 (ja) | 2013-03-14 | 2020-01-15 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | タウ発現を調節するための組成物および方法 |
PL2992009T3 (pl) | 2013-05-01 | 2020-11-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji apolipoproteiny(a) |
PE20160158A1 (es) | 2013-06-27 | 2016-03-18 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en pcsk9 |
US20170073689A1 (en) | 2013-07-02 | 2017-03-16 | Ionis Pharmaceuticals, Inc. | Modulators of growth hormone receptor |
TW202246503A (zh) * | 2013-07-19 | 2022-12-01 | 美商百健Ma公司 | 用於調節τ蛋白表現之組合物 |
US20160319361A1 (en) | 2013-08-28 | 2016-11-03 | Caris Life Sciences Switzerland Holdings Gmbh | Oligonucleotide probes and uses thereof |
EP3099685B1 (en) | 2014-01-30 | 2018-04-18 | F.Hoffmann-La Roche Ag | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
CA2935426C (en) | 2014-01-30 | 2023-07-25 | F. Hoffmann-La Roche Ag | Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target |
WO2015173164A1 (en) | 2014-05-13 | 2015-11-19 | F. Hoffmann-La Roche Ag | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
US20170211064A1 (en) * | 2014-07-29 | 2017-07-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
SG11201702877TA (en) | 2014-10-10 | 2017-05-30 | Hoffmann La Roche | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
EP3221329A1 (en) | 2014-11-19 | 2017-09-27 | Roche Innovation Center Copenhagen A/S | Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages |
US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
MX2017010066A (es) * | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
CN107207505B (zh) | 2015-02-11 | 2018-12-14 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物 |
WO2016151523A1 (en) | 2015-03-25 | 2016-09-29 | Università Degli Studi Di Trento | Rna interference mediated therapy for neurodegenerative diseases |
JP6462155B2 (ja) | 2015-05-04 | 2019-01-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B型肝炎ウイルス感染症の治療用のHBsAg(HBV表面抗原)及びHBV DNA産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 |
WO2017009679A1 (en) | 2015-07-13 | 2017-01-19 | Otis Elevator Company | Deterrent device inhibition key |
EP3325097B1 (en) | 2015-07-17 | 2021-09-01 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
CN115957337A (zh) | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
WO2017066712A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
EP3390634A4 (en) | 2015-12-14 | 2019-08-14 | Cold Spring Harbor Laboratory | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES |
JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
KR102468177B1 (ko) | 2016-04-14 | 2022-11-16 | 에프. 호프만-라 로슈 아게 | 트리틸-모노-GalNAc 화합물 및 이의 용도 |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
WO2018059718A1 (en) | 2016-09-30 | 2018-04-05 | Rijk Zwaan Zaadteelt En Zaadhandel B.V. | Peronospora resistance in spinacia oleracea |
SG11202003461TA (en) | 2017-10-16 | 2020-05-28 | Hoffmann La Roche | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION |
CA3088066A1 (en) | 2018-01-29 | 2019-08-01 | F. Hoffmann-La Roche Ag | Process for the preparation of galnac oligonucleotide conjugates |
CA3103054A1 (en) | 2018-07-03 | 2020-01-09 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating tau expression |
-
2019
- 2019-07-03 CA CA3103054A patent/CA3103054A1/en active Pending
- 2019-07-03 MX MX2020013366A patent/MX2020013366A/es unknown
- 2019-07-03 TW TW108123491A patent/TW202020151A/zh unknown
- 2019-07-03 CN CN201980044785.3A patent/CN112567033A/zh active Pending
- 2019-07-03 EP EP19742115.9A patent/EP3818159A1/en active Pending
- 2019-07-03 CR CR20210178A patent/CR20210178A/es unknown
- 2019-07-03 JP JP2020573180A patent/JP7102557B2/ja active Active
- 2019-07-03 US US16/503,340 patent/US11279929B2/en active Active
- 2019-07-03 KR KR1020237033595A patent/KR20230143199A/ko not_active Application Discontinuation
- 2019-07-03 WO PCT/EP2019/067799 patent/WO2020007892A1/en active Application Filing
- 2019-07-03 CR CR20210058A patent/CR20210058A/es unknown
- 2019-07-03 AU AU2019297391A patent/AU2019297391B2/en active Active
- 2019-07-03 PE PE2020001998A patent/PE20210346A1/es unknown
- 2019-07-03 RU RU2021101957A patent/RU2768285C1/ru active
- 2019-07-03 SG SG11202012759XA patent/SG11202012759XA/en unknown
- 2019-07-03 BR BR112020026973-5A patent/BR112020026973A2/pt unknown
- 2019-07-03 PE PE2021000777A patent/PE20220013A1/es unknown
- 2019-07-03 CR CR20210179A patent/CR20210179A/es unknown
- 2019-07-03 KR KR1020217003289A patent/KR102585973B1/ko active IP Right Grant
-
2020
- 2020-11-29 IL IL279056A patent/IL279056A/en unknown
- 2020-12-29 PH PH12020552276A patent/PH12020552276A1/en unknown
- 2020-12-31 US US17/139,161 patent/US11753640B2/en active Active
- 2020-12-31 CL CL2020003457A patent/CL2020003457A1/es unknown
-
2021
- 2021-04-26 CL CL2021001071A patent/CL2021001071A1/es unknown
- 2021-04-26 CL CL2021001072A patent/CL2021001072A1/es unknown
-
2022
- 2022-01-21 US US17/581,855 patent/US20220177884A1/en active Pending
- 2022-07-05 JP JP2022108490A patent/JP2022141739A/ja active Pending
-
2023
- 2023-04-12 AU AU2023202255A patent/AU2023202255A1/en active Pending
- 2023-07-21 US US18/356,770 patent/US20240026360A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003457A1 (es) | Oligonucleótidos para modular la expresión de tau | |
CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
CL2016002751A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
ECSP099061A (es) | Moduladores de benzofuro- y benzotienopirimidina | |
CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
CR20110103A (es) | Heteroarilos sustituidos | |
NI200900159A (es) | Moduladores de 2-aminopirimidina del receptor de histamina h4. | |
PH12016501791A1 (en) | Muscarinic receptor agonists | |
BR112015022156A2 (pt) | composições e métodos para modular a expressão de tau | |
PA8808201A1 (es) | Moduladores imidazolo-,oxazolo-, y tiazolopirimidina del trpvi | |
CL2017003124A1 (es) | Moduladores alostéricos positivos del receptor de m2 muscarínico | |
EA201891854A1 (ru) | Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m | |
CL2015002434A1 (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina. | |
NI201000214A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4. | |
CY1118044T1 (el) | Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες | |
CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
BR112023020781A2 (pt) | Moduladores de cbl-b e usos dos mesmos | |
CL2016000677A1 (es) | Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2. | |
CL2020002038A1 (es) | Oligonucleótidos para modular la expresión de tmem106b. | |
UY32641A (es) | Compuestos con dos porciones heteroarilo bicíclicas fusionadas como moduladores de la hidrolasa de leucotrieno a4 | |
AR116104A1 (es) | Oligonucleótidos para modular la expresión de tau | |
CU20180044A7 (es) | Derivados novedosos de diamino piridina | |
BR112017019154A2 (pt) | uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica | |
CL2022002713A1 (es) | Oligonucleótidos para modular la expresión de tau (divisional solicitud no. 202003457) | |
CL2015000416A1 (es) | Compuestos derivados de diazepinona; composicion y combinacion farmaceutica que los comprende, util para el tratamiento de un trastorno o enfermedad mediada por mglur5 tal como sindrome x fragil, enfermedad de parkinson o enfermedad de reflujo. |